Myositis in Pediatrics: Diagnostic Workup and Treatment
All children with suspected myositis should be immediately referred to a specialized center, with urgent referral required for high-risk features including severe disability, aspiration/dysphagia, gastrointestinal vasculitis, myocarditis, parenchymal lung disease, or age <1 year 1.
Diagnostic Workup
Initial Laboratory Investigations
When evaluating a pediatric patient for suspected myositis, obtain the following essential tests 1:
- Muscle enzymes: CPK, LDH, AST, ALT, aldolase
- Complete blood count with blood film
- Inflammatory markers: ESR and CRP
- Myositis-specific and myositis-associated autoantibodies (critical for phenotype identification and prognosis) 2, 3
- Renal and liver function tests
- Infection screen (to exclude viral myositis)
- Endocrine evaluation: thyroid function, electrolytes, vitamin D
- Metabolic/mitochondrial workup if presentation is atypical or rash is absent
- Urinalysis with protein evaluation if positive
Imaging and Specialized Studies
- Nailfold capillaroscopy 1
- Echocardiogram and ECG to assess for myocarditis 1
- Pulmonary function tests, chest X-ray, and HRCT to evaluate for interstitial lung disease 1
- MRI (T1, T2, fat suppression sequences, STIR) to identify optimal biopsy site and monitor treatment response 2
Critical Diagnostic Caveat
If cutaneous signs are absent or the patient fails to respond as expected to therapy, strongly consider alternative diagnoses including metabolic myopathies, mitochondrial disorders, and muscular dystrophies 1. This is a common pitfall—juvenile dermatomyositis (JDM) is the most common pediatric myositis, but benign acute viral myositis following influenza infection is also frequent in school-age children and presents with calf pain, elevated CPK, and self-limited course 4, 5.
Treatment Approach
For Uncomplicated Juvenile Dermatomyositis
Begin corticosteroids at 2 mg/kg/day (maximum 60 mg/day) with subcutaneous methotrexate 15 mg/m² weekly initiated simultaneously at treatment onset 2. This represents the most recent guideline-based recommendation prioritizing early steroid-sparing agent use.
- Taper corticosteroids after 2-4 weeks depending on patient response 2
- The concurrent initiation of methotrexate (rather than sequential addition) minimizes cumulative steroid exposure and associated morbidity
For Severe or Refractory Disease
High-risk patients require aggressive therapy with high-dose intravenous methylprednisolone plus one of the following: intravenous immunoglobulin, cyclophosphamide, rituximab, or cyclosporine 2.
High-risk features warranting this approach include 1:
- Severe disability (inability to get off bed)
- CMAS score <15 or MMT8 score <30
- Aspiration or dysphagia preventing swallowing
- Gastrointestinal vasculitis (imaging or bloody stools)
- Myocarditis
- Parenchymal lung disease
- CNS involvement (decreased consciousness, seizures)
- Skin ulceration
- ICU-level care requirement
- Age <1 year
Monitoring and Disease Assessment
Use validated tools to assess disease activity regularly 1:
- Disease Activity Score for muscle, skin, and major organ involvement
- Patient/parent-reported outcomes (Childhood Health Assessment Questionnaire, visual analogue scales)
- Myositis Damage Index assessed at least yearly to track cumulative damage 1
The 2017 consensus guidelines emphasize that standardized monitoring of treatment response, including disease activity measurement and adverse effects of immunosuppression, is a cornerstone of management 1. Novel biomarkers like interleukin-6 and type I interferon-regulated genes may serve as disease activity indicators 2, with JDM now conceptualized as an acquired interferonopathy 3.
Emerging Therapies
For severe, treatment-refractory cases, Janus-kinase inhibitors represent a novel therapeutic option based on the pathophysiological understanding of type I interferon involvement in JDM 3.
Key Clinical Pitfall
The most important distinction is between autoimmune inflammatory myopathies (JDM) requiring immunosuppression versus benign acute viral myositis requiring only supportive care. Viral myositis typically follows influenza infection, presents with symmetric calf pain and gait difficulty, has elevated CPK, but is self-limited and resolves with hydration and fever control alone 4, 5. Missing this distinction leads to either unnecessary immunosuppression or dangerous undertreatment of true JDM.